# Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.

> **NCT04131322** · PHASE4 · TERMINATED · sponsor: **Fundación Pública Andaluza para la gestión de la Investigación en Sevilla** · enrollment: 24 (actual)

## Conditions studied

- Crohn Disease
- Ulcerative Colitis

## Interventions

- **DRUG:** Amgevita 40Mg Solution for Injection
- **DRUG:** HUMIRA 40Mg Solution for Injection

## Key facts

- **NCT ID:** NCT04131322
- **Lead sponsor:** Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-10
- **Primary completion:** 2020-06-08
- **Final completion:** 2020-06-08
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Sponsor cancellation
- **Last updated:** 2021-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04131322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04131322, "Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04131322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*